bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets
Authors: Stefanska Barbara , Cheishvili David , Suderman Matthew , Arakelian Ani , Huang Jian , Hallett Michael , Han Ze-Guang , Al-Mahtab Mamun , Akbar Sheikh Mohammad Fazle , Khan Wasif Ali , Raqib Rubhana , Tanvir Imrana , Khan Haseeb Ahmed , Rabbani Shafaat A. , Szyf Moshe
Published: April 2023

PDF file - 774KB, Supplementary Figure S3. RASAL2 and NENF are overexpressed in different types of human cancers. RASAL2 or NENF depletion decreases cancer cell growth and invasive capacities in liver cancer. Changes defined using different siRNA sequences (siRASAL2-1 and siNENF-1) than in Figure 2-4. (A) Cancer gene expression microarray data for RASAL2 and NENF. The normal versus tumor gene expression data were obtained from Oncomine and are presented as log2-transformed median centered per array, and SD-normalized to 1 per array. All the presented changes are statistically significant (P < 0.05). (B,E) Expression of the depleted genes, RASAL2 and NENF, quantified by QPCR after first (I), second (II) and third (III) transfection of HepG2 (B) and SkHep1 (E) with scrambled siRNA (siCtrl) and siRNA directed to RASAL2 (siRASAL2-1) or NENF (siNENF-1). (C,F) Effect on cell growth after first (day 3), second (day 6) and third (day 9) transfection with siRASAL2-1 or siNENF-1 in HepG2 (C) and SkHep1 (F) cells. (D,G) Effect on cell invasion as measured by Boyden chamber invasion assay after second transfection with siRASAL2-1 or siNENF-1 in HepG2 (D) and SkHep1 (G) cells. All results represent mean � S.D. of three determinations in either two or three independent experiments - ***P < 0.001, **P < 0.01, *P < 0.05. (H) Expression of RASAL2 and NENF in HCC (n=3) and CHB (chronic hepatitis B infection - cirrhosis, n=3) samples from Bangladeshi cohort as measured by QPCR. Each point represents a value for one sample. All patients provided written informed consent, and the Ethics Committee from Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh approved the study. Bangladeshi cohort consisted of 4 HCC patients and 4 CHB patients in Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh (Table 2). The HCC samples were obtained at ultrasonogram guided fine needle aspiration, while the CHB samples were obtained at per-cutaneous liver biopsy using Tru-cut biopsy needle. In both cases local anaesthesia was used. International Centre for Diarrhoeal Diseases Research, Bangladesh (icddr,b) acknowledges with gratitude the commitment of donors to the Centre's research efforts.
Figure-S4 from ASS1 as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic Relevance
Authors: Huang Hsuan-Ying , Wu Wen-Ren , Wang Yu-Hui , Wang Jun-Wen , Fang Fu-Min , Tsai Jen-Wei , Li Shau-Hsuan , Hung Hsiao-Chin , Yu Shih-Chen , Lan Jui , Shiue Yow-Ling , Hsing Chung-His , Chen Li-Tzong , Li Chien-Feng
Published: April 2023

Figure-S4 PDF file 86K, Figure-S4 ASS1 reexpression induces cell cycle arrest at the G1 phase in myxofibrosarcoma cells with consistent downregulation of cyclin E expression. Left panel: As analyzed by flow cytometry, cell cycle distribution in one each representative experiment is shown for OH931 (upper), NMFH-1 (middle), and NMFH-2 (lower) cells stably transfected with either ASS1-expressing or empty control vectors. Right panel: In the corresponding histograms, a significant increase of tumors cells distributed at the G1 phase with concomitantly decreased cell percentages at the S and G2 phases are detected in OH931 and NMFH-2 cell lines, while this effect on cell cycle is not apparent in NMFH-1 cell line. Error bars denote the range of values derived from triplicate experiments. Lower panel: Western blotting assays against cyclins and cyclin-dependent kinases associated with regulation of G1 phase and G1/S transition show consistent suppression of cyclin E in all three myxofibrosarcoma cell lines upon stable transfection of ASS1. However, CDK2 is randomly downregulated in ASS1-reexpressing NMFH-2 cells alone
Supplementary Table 1 from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
Authors: Kim Beom Kyung , Kim Seung Up , Kim Myeong-Jin , Kim Kyung Ah , Kim Do Young , Park Jun Yong , Ahn Sang Hoon , Han Kwang-Hyub , Chon Chae Yoon
Published: April 2023

PDF file - 125K, Inter-observer agreements according to radiological methods regarding treatment responses (CR, PR, SD, and PD)
Supplementary Table 3 from Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy
Authors: Gold Kathryn A. , Kim Edward S. , Liu Diane D. , Yuan Ping , Behrens Carmen , Solis Luisa M. , Kadara Humam , Rice David C. , Wistuba Ignacio I. , Swisher Stephen G. , Hofstetter Wayne L. , Lee J. Jack , Hong Waun K.
Published: April 2023

PDF file - 66K, Multicovariate Cox model for OS in stage I NSCLC.
Supplementary Table 2 from Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy
Authors: Gold Kathryn A. , Kim Edward S. , Liu Diane D. , Yuan Ping , Behrens Carmen , Solis Luisa M. , Kadara Humam , Rice David C. , Wistuba Ignacio I. , Swisher Stephen G. , Hofstetter Wayne L. , Lee J. Jack , Hong Waun K.
Published: April 2023

PDF file - 68K, Multicovariate Cox model for RFS in stage I NSCLC.
Supplementary Figure Legend from Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization
Authors: Kim Beom Kyung , Kim Seung Up , Kim Myeong-Jin , Kim Kyung Ah , Kim Do Young , Park Jun Yong , Ahn Sang Hoon , Han Kwang-Hyub , Chon Chae Yoon
Published: April 2023

PDF file - 107K
Supplementary Materials and Methods from Myeloid Differentiation Factor 88 Promotes Growth and Metastasis of Human Hepatocellular Carcinoma
Authors: Liang Beibei , Chen Rui , Wang Tao , Cao Lei , Liu Yingying , Yin Fan , Zhu Minhui , Fan Xiaoyu , Liang Yingchao , Zhang Lu , Guo Yajun , Zhao Jian
Published: April 2023

PDF File - 154K, Description of materials and methods in supplementary data
Supplementary Information from TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2–Expressing Monocytes in Human Breast Tumors
Authors: Ibberson Mark , Bron Sylvian , Guex Nicolas , Faes-van't Hull Eveline , Ifticene-Treboux Assia , Henry Luc , Lehr Hans-Anton , Delaloye Jean-François , Coukos George , Xenarios Ioannis , Doucey Marie-Agnès
Published: April 2023

Supplementary Information - PDF file 145K, Supplementary Material and Methods; Supplementary Figure Legend S1 (Proliferation of tumor-specific CD4 T cells by matured DC pulsed with autologous tumor lysate.); Supplementary Figure Legend S2 (In breast tumors TEM and CD11c+ are distinct cell subsets.); Supplementary Tables S1 (Clinical and pathological features of tumors and patients (n=40)); Supplementary Tables S2 (CD11c+ DC and TEM from breast tumors were exposed to autologous CFSE-labeled T cells and their proliferation assessed five days later by flow cytometry.); Supplementary References
Supplementary Table 2 from Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer
Authors: Davis Sally J. , Sheppard Karen E. , Pearson Richard B. , Campbell Ian G. , Gorringe Kylie L. , Simpson Kaylene J.
Published: April 2023

PDF file - 75K, Oligonucleotides
Supplementary Figure 2 from Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer
Authors: Davis Sally J. , Sheppard Karen E. , Pearson Richard B. , Campbell Ian G. , Gorringe Kylie L. , Simpson Kaylene J.
Published: April 2023

PDF file - 126K, TPX2 amplification is protective against loss of cellular viability in ovarian tumor cells
Supplementary Table 1 from Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line Treatment
Authors: Bauer Robert C. , Sänger Jana , Peschel Christian , Duyster Justus , von Bubnoff Nikolas
Published: April 2023

PDF File - 120K, BCR-ABL kinase domain mutations recovered in the sequential screen with IC50-values for imatinib, dasatinib and nilotinib.
Related Article from Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer
Authors: Politi Katerina , Lynch Thomas J.
Published: April 2023

Related Article from Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer
Supplementary Information from Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer
Authors: Lange Tobias , Kupfernagel Mareike , Wicklein Daniel , Gebauer Florian , Maar Hanna , Brügge Kathrin , Müller Imke , Simon Ronald , Schlomm Thorsten , Sauter Guido , Schumacher Udo
Published: April 2023

PDF file 114K, supplementary M&M sections, Results and Figure Legends
Supplementary Figure S1 from Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer
Authors: Lange Tobias , Kupfernagel Mareike , Wicklein Daniel , Gebauer Florian , Maar Hanna , Brügge Kathrin , Müller Imke , Simon Ronald , Schlomm Thorsten , Sauter Guido , Schumacher Udo
Published: April 2023

PDF file 230K, Selectin ligands, selectin binding and dynamic adhesion of PCa cells
Supplementary Tables 1 - 5 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
Authors: Anitei Maria-Gabriela , Zeitoun Guy , Mlecnik Bernhard , Marliot Florence , Haicheur Nacilla , Todosi Ana-Maria , Kirilovsky Amos , Lagorce Christine , Bindea Gabriela , Ferariu Dan , Danciu Mihai , Bruneval Patrick , Scripcariu Viorel , Chevallier Jean-Marc , Zinzindohoué Franck , Berger Anne , Galon Jérôme , Pagès Franck
Published: April 2023

PDF file - 107KB, Table 1. characteristics of the HEGP cohort of rectal cancer patients. Table 2. Characteristics of the St Spiridon Hospital cohort of patients. Table 3. Immune infiltration of CD3+ and CD8+ cells in tumor regions and clinical outcome. Cohort of 111 patients eligible to primary surgery. Table 4. Patients at risk at each interval in the Kaplan Meier survival curves for the duration of DFS and OS according to the Immunoscore (CD3-CD8). Table 5. Repartition of the "surgery cohort" patient's according to Stage and Immunoscore.
Supplementary Tables 1 - 5 from Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
Authors: Anitei Maria-Gabriela , Zeitoun Guy , Mlecnik Bernhard , Marliot Florence , Haicheur Nacilla , Todosi Ana-Maria , Kirilovsky Amos , Lagorce Christine , Bindea Gabriela , Ferariu Dan , Danciu Mihai , Bruneval Patrick , Scripcariu Viorel , Chevallier Jean-Marc , Zinzindohoué Franck , Berger Anne , Galon Jérôme , Pagès Franck
Published: April 2023

Supplementary Table 1: characteristics of the HEGP cohort of rectal cancer patients Supplementary Table 2: Characteristics of the St Spiridon Hospital cohort of patients Supplementary Table 3: Immune infiltration of CD3+ and CD8+ cells in tumor regions and clinical outcome. Cohort of 111 patients eligible to primary surgery. Supplementary Table 4: Patients at risk at each interval in the Kaplan Meier survival curves for the duration of DFS and OS according to the Immunoscore (CD3-CD8). Supplementary Table 5: Repartition of the "surgery cohort" patient's according to Stage and Immunoscore
Appendix from Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non–Small Cell Lung Cancer
Authors: Win Thida , Miles Kenneth A. , Janes Sam M. , Ganeshan Balaji , Shastry Manu , Endozo Raymondo , Meagher Marie , Shortman Robert I. , Wan Simon , Kayani Irfan , Ell Peter J. , Groves Ashley M.
Published: April 2023

Appendix - PDF file 148K, This section contains technical and statistical information regarding textural analysis, as well as supplementary survival analysis
Supplementary Figure 1 from Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Authors: Tagawa Scott T. , Milowsky Matthew I. , Morris Michael , Vallabhajosula Shankar , Christos Paul , Akhtar Naveed H. , Osborne Joseph , Goldsmith Stanley J. , Larson Steve , Taskar Neeta Pandit , Scher Howard I. , Bander Neil H. , Nanus David M.
Published: April 2023

PDF file - 117K, Supplemental Figure 1A: PSA waterfall plots by dose received. Each individual subjects best PSA response on study. The top figure depicts those subjects who received 65 mCi/m2 and the bottom figure depicts those who received 70 mCi/m2 (the phase I maximum tolerated dose). Supplemental Figure 1B: Circulating Tumor Cell Count waterfall plot Each individual subjects % change in CTC count from baseline to 4-6 weeks following therapy with 70 mCi/m2 of 177Lu-J591. Using the 5 CTC/7.5 mL cutoff, 6 began and remained favorable, 3 converted from unfavorable to favorable (7-->3, 18-->0, 34-->0), and 3 had decline in counts, but remained unfavorable (161-->118, 228-->110, 60-->16). Three subjects had 0 CTCs per 7.5 mL blood at baseline and remained with 0 at follow up. Supplemental Figure 1C: Change in measurable disease Each individual subject with measurable disease is depicted with % change in sum of unidimensional measurements (RECIST). Dose of 177Lu-J591 received is indicted by color.
Supplementary Figure 8 from Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Authors: Flanigan Sara A. , Pitts Todd M. , Newton Timothy P. , Kulikowski Gillian N. , Tan Aik Choon , McManus Martine C. , Spreafico Anna , Kachaeva Maria I. , Selby Heather M. , Tentler John J. , Eckhardt S. Gail , Leong Stephen
Published: April 2023

Supplementary Figure 8 - PDF file 82K, Densitometry Analysis of Westerns
Supplementary Figure S2 from Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Authors: Fjeldbo Christina S. , Julin Cathinka H. , Lando Malin , Forsberg Malin F. , Aarnes Eva-Katrine , Alsner Jan , Kristensen Gunnar B. , Malinen Eirik , Lyng Heidi
Published: April 2023

Comparing Illumina and RT-qPCR gene expression data.
Supplementary Methods from Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome
Authors: Karlsson Anna , Jönsson Mats , Lauss Martin , Brunnström Hans , Jönsson Per , Borg Åke , Jönsson Göran , Ringnér Markus , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Methods. Document describing in detail the different cohorts and data processing steps used.
Supplementary Figures 1-6 from Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome
Authors: Karlsson Anna , Jönsson Mats , Lauss Martin , Brunnström Hans , Jönsson Per , Borg Åke , Jönsson Göran , Ringnér Markus , Planck Maria , Staaf Johan
Published: April 2023

Supplementary Figures 1-6. PDF containing six supplementary figures. Figure S1: Identification and validation of epitypes in the discovery cohort. Figure S2: Reproducibility of epitypes in the Sandoval et al. cohort. Figure S3: Reproducibility of epitypes in the TCGA cohort. Figure S4: Mutation transversions across epitypes for TCGA adenocarcinomas stratified by smoking status. Figure S5: Copy number alterations (CNAs) and genomic complexity in adenocarcinoma epitypes. Figure S6: Promoter and global hypermethylation with respect to smoking status and adenocarcinoma gene expression subtypes.
Supplementary Figures 1 - 4 from Association of Interleukin-28B Genotype and Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
Authors: Hodo Yuji , Honda Masao , Tanaka Akihiro , Nomura Yoshimoto , Arai Kuniaki , Yamashita Taro , Sakai Yoshio , Yamashita Tatsuya , Mizukoshi Eishiro , Sakai Akito , Sasaki Motoko , Nakanuma Yasuni , Moriyama Mitsuhiko , Kaneko Shuichi
Published: April 2023

PDF file - 901K, Figure S1: Schematic presentation of patients with HCC; Figure S2: One way hierarchical clustering of 122 genes involved in the gene set differentially expressed in HCC-infiltrating mononuclear inflammatory cells of 20 patients with the IL28B genotype; Figure S3: Kaplan-Meier curves of time to late recurrence (>1year) in relation to IL28B genotype; Figure S4: One way hierarchical clustering of 14 intratumoral immune genes of 20 patients with the IL28B genotype.
Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Authors: Wardell Suzanne E. , Ellis Matthew J. , Alley Holly M. , Eisele Koleen , VanArsdale Todd , Dann Stephen G. , Arndt Kim T. , Primeau Tina , Griffin Elizabeth , Shao Jieya , Crowder Robert , Lai Jin-Ping , Norris John D. , McDonnell Donald P. , Li Shunqiang
Published: April 2023

Supplemental figure 4: Evaluation of pharmacodynamics endpoints confirms on target activity of SERDs and palbociclib, resulting in sustained inhibition of tumors receiving both treatments
Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Authors: Wardell Suzanne E. , Ellis Matthew J. , Alley Holly M. , Eisele Koleen , VanArsdale Todd , Dann Stephen G. , Arndt Kim T. , Primeau Tina , Griffin Elizabeth , Shao Jieya , Crowder Robert , Lai Jin-Ping , Norris John D. , McDonnell Donald P. , Li Shunqiang
Published: April 2023

Supplemental figure 3: SERDs and palbociclib inhibit breast cancer cell proliferation by independent mechanisms
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Authors: Wardell Suzanne E. , Ellis Matthew J. , Alley Holly M. , Eisele Koleen , VanArsdale Todd , Dann Stephen G. , Arndt Kim T. , Primeau Tina , Griffin Elizabeth , Shao Jieya , Crowder Robert , Lai Jin-Ping , Norris John D. , McDonnell Donald P. , Li Shunqiang
Published: April 2023

Supplemental figure 2: SERDs inhibit the constitutive activity of the clinically relevant Y537N,D538G ESR1 double mutant
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Authors: Wardell Suzanne E. , Ellis Matthew J. , Alley Holly M. , Eisele Koleen , VanArsdale Todd , Dann Stephen G. , Arndt Kim T. , Primeau Tina , Griffin Elizabeth , Shao Jieya , Crowder Robert , Lai Jin-Ping , Norris John D. , McDonnell Donald P. , Li Shunqiang
Published: April 2023

Supplemental figure 1: SERDs and SERMs differ in their ability to inhibit ER-dependent stimulation of breast cancer cell proliferation by growth factors
Supplementary figure 1 from Intratumor Heterogeneity in Hepatocellular Carcinoma
Authors: Friemel Juliane , Rechsteiner Markus , Frick Lukas , Böhm Friederike , Struckmann Kirsten , Egger Michèle , Moch Holger , Heikenwalder Mathias , Weber Achim
Published: April 2023

Supplementary figure 1. quantification of reading Errors
Supplementary Figures from HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Authors: Zheng Hong , Zhao Weipeng , Yan Cihui , Watson Crystina C. , Massengill Michael , Xie Mengyu , Massengill Chris , Noyes David R. , Martinez Gary V. , Afzal Roha , Chen Zhihua , Ren Xiubao , Antonia Scott J. , Haura Eric B. , Ruffell Brian , Beg Amer A.
Published: April 2023

Fig. S1. Screening of oncology drugs to identify agents with immuno-stimulatory properties. Fig. S2. Expression of Ccl5, Cxcl9 and Cxcl10 was normalized to ribosomal 18s RNA and is shown as fold change compared to DMSO treated LKR (set at 1). Fig. S3. Treatment regimen of mice receiving i.p. anti-CD4/CD8 and romidepsin. Fig. S4. Percentage of CD4 or CD8 in DAPI- (viable) peripheral blood of mice receiving anti- CD8 or anti-CD4 at 300mug, as indicated. Fig. S5. PD-L1 expression. Cell surface expression of PD-L1 determined by FACS in viable LKR, 393P (393) and 344SQ (344) cells after 24h treatment with 30nM romidepsin or IFNgamma as indicated. UT: untreated cells. Fig. S6. (A) Impact of romidepsin (n=6) and anti-PD-1 (n=7) treatment on LKR tumor growth for 47 days. Fig. S7. 129 mice were inoculated s.c. with 106 344SQ (344) following which they were treated with 2mg/kg romidepsin on days 14,16,18, with or without 300μg/mouse anti-PD-1 antibody on days 15,17,19 as indicated. Fig. S8. (A) Heatmap analysis using conventional red-green scale of microarray results of LKR cells after IFNgamma and/or romidepsin treatment for genes increased after combined vs. single treatments. Fig. S9. (A) 129 mice with day 14 tumors were untreated (UT) or treated with romidepsin on days 14 and 16 and anti-PD-1 antibody on days 15 and 17 (RP) after which FACS was used to determine CD4 (CD3+CD4+) and CD8 (CD3+CD8+) percentages in total viable cells (day 19). Fig. S10. 129 mice were inoculated s.c. with 106 LKR cells. Effect of romidepsin (Rom) treatment (2mg/kg on days 14,16,18) on tumor growth over indicated time periods is shown. Fig. S11. 129 mice were i.p. injected with 2mg/kg romidepsin twice. 48h after the last injection, MDSC cells (CD11b+ Gr1 + Ly- 6G +) from blood of mice (n=3) were analyzed by FACS. Fig. S12. Western blot analysis of LKR cells treated with Romidepsin (Rom) and/ or IFNgamma as indicated. STAT1 levels are shown in whole cell lysates and β-actin levels are indicated as controls
Supplementary table S1 from Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models
Authors: Sladkevicius Povilas , Valentin Lil
Published: April 2023

Supplementary table S1. It shows how inter-observer agreement for discrete variables differed depending on the intervals between examinations of adnexal masses by each observer.
Supplemental Table 4 from A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy
Authors: Saridaki Zenia , Weidhaas Joanne B. , Lenz Heinz-Josef , Laurent-Puig Pierre , Jacobs Bart , De Schutter Jef , De Roock Wendy , Salzman David W. , Zhang Wu , Yang Dongyun , Pilati Camilla , Bouché Olivier , Piessevaux Hubert , Tejpar Sabine
Published: April 2023

Predictive and prognostic factors by multivariate analyses (adjusted relative risks) for PFS and OS. A. Univariate analysis B. Multivariate analysis.
Supplementary Table 4 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Authors: Beltran Pedro J. , Calzone Frank J. , Mitchell Petia , Chung Young-Ah , Cajulis Elaina , Moody Gordon , Belmontes Brian , Li Chi-Ming , Vonderfecht Steven , Velculescu Victor E. , Yang Guorong , Qi Jingwei , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 47KB, Expression analysis in ovarian cancer cell lines.
Supplementary Table 2 from Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Authors: Beltran Pedro J. , Calzone Frank J. , Mitchell Petia , Chung Young-Ah , Cajulis Elaina , Moody Gordon , Belmontes Brian , Li Chi-Ming , Vonderfecht Steven , Velculescu Victor E. , Yang Guorong , Qi Jingwei , Slamon Dennis J. , Konecny Gottfried E.
Published: April 2023

PDF file - 37KB, Primer sequences.
supplemental legend from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

supplemental legend
Supplementary Figure 5 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Authors: Srivastava Raghvendra M. , Lee Steve C. , Andrade Filho Pedro A. , Lord Christopher A. , Jie Hyun-Bae , Davidson H. Carter , López-Albaitero Andrés , Gibson Sandra P. , Gooding William E. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

PDF file - 471K, Enhancement of DC maturation by IL-2 activated NK cells.
Supplementary Figure 4 from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Authors: Srivastava Raghvendra M. , Lee Steve C. , Andrade Filho Pedro A. , Lord Christopher A. , Jie Hyun-Bae , Davidson H. Carter , López-Albaitero Andrés , Gibson Sandra P. , Gooding William E. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

PDF file - 160K, The absence of cetuximab in the NK:DC co-culture (without HNC cells) or DC:PCI-15B co-culture (without NK cells) abrogated the IFN-γ secretion.
Supplementary Figure 3B from Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients
Authors: Srivastava Raghvendra M. , Lee Steve C. , Andrade Filho Pedro A. , Lord Christopher A. , Jie Hyun-Bae , Davidson H. Carter , López-Albaitero Andrés , Gibson Sandra P. , Gooding William E. , Ferrone Soldano , Ferris Robert L.
Published: April 2023

PDF file - 386K, Importance of IFN-γ released by cetuximab activated NK cells in the enhancement of DC maturation.
Data Supplement from PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
Authors: Rahmani Mohamed , Aust Mandy Mayo , Benson Elisa C. , Wallace LaShanale , Friedberg Jonathan , Grant Steven
Published: April 2023

Supplementary Fig. 1: Ectopic expression of constitutively active AKT diminished panobinostat toxicity. Supplementary Fig. 2: BEZ235 and panobinostat interact synergistically to kill NHL cell lines. Supplementary Fig. 3: Effects of BEZ235 and panobinostat coadministration on histone acetylation, DNA damage and p21CIP1 expression. Supplementary Fig. 4: Role of Bim in BEZ235/panobinostat toxicity. Supplementary Fig. 5: Effects of BEZ235/panobinostat on Bax, Bak, or Bim binding to Bcl-2, Bcl-xL or Mcl-1 proteins. Supplementary Fig. 6: BEZ235/panobinostat toxicity involves Bax and Bak Supplementary Fig. 7: BEZ235/panobinostat activity in the presence of HS-5-conditioned media. Supplementary Fig. 8: Effect of BEZ235/panobinostat on animal weight
Supplemental figures from Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma
Authors: Mao Yumeng , Eissler Nina , Blanc Katarina Le , Johnsen John Inge , Kogner Per , Kiessling Rolf
Published: April 2023

Figure S1. A) Expression levels of granulocytic marker CD66b, regulatory T cell marker FoxP3 or dendritic cell marker CD83, CD11c Figure S2. A) CD34+ hematopoietic stem cells without cytokine activation lack the capacity to stimulate allogeneic T cells. Figure S3. Analysis of A) M-CSF or B) 27 other soluble factors produced by the three human neuroblastoma cell lines (SK-N-BE(2), SK-N-AS or SK-N-FI). Figure S4. Expression of PD-L1 on A) tumor-educated monocytes Figure S5. Bone marrow cells extracted from naÃƒÂ¯ve mice were cultured in medium, recombinant murine M-CSF (20 ng/ml) or neuroblastoma tumor-conditioned medium (TCM). Figure S6. Mice were sacrificed 10 days after spontaneous tumors were palpable Figure S7. A) BLZ945 treatment scheme in the TH-MYCN mice bearing established spontaneous tumors was summarized. Figure S8. A) Treatment scheme combining PD-1/PD-L1 blockade and CSF-1R inhibition was illustrated.
Supplementary Table 1 from Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Authors: Eng Lawson , Azad Abul Kalam , Habbous Steven , Pang Vincent , Xu Wei , Maitland-van der Zee Anke H. , Savas Sevtap , Mackay Helen J. , Amir Eitan , Liu Geoffrey
Published: April 2023

PDF file, 59K, Supplementary Table 1: Summary of sequence variants/polymorphisms found in systematic review and their common, Human Genome Variation Society (HGVS) and RefSNP annotations.
Supplementary Figure 5 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Authors: Rivera Zeyana , Ferrone Soldano , Wang Xinhui , Jube Sandro , Yang Haining , Pass Harvey I. , Kanodia Shreya , Gaudino Giovanni , Carbone Michele
Published: April 2023

PDF file, 3582K, CSPG4-specific mAb TP41.2 reduces MM wound healing.
Supplementary Figure 4 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Authors: Rivera Zeyana , Ferrone Soldano , Wang Xinhui , Jube Sandro , Yang Haining , Pass Harvey I. , Kanodia Shreya , Gaudino Giovanni , Carbone Michele
Published: April 2023

PDF file, 2167K, CSPG4 knockdown reduces MM cell migration.
Supplementary Figure S1. Flow chart of LN sampling and RT-PCR. from Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial
Authors: Yamamoto Hirofumi , Murata Kohei , Fukunaga Mutsumi , Ohnishi Tadashi , Noura Shingo , Miyake Yasuhiro , Kato Takeshi , Ohtsuka Masahisa , Nakamura Yurika , Takemasa Ichiro , Mizushima Tsunekazu , Ikeda Masataka , Ohue Masayuki , Sekimoto Mitsugu , Nezu Riichiro , Matsuura Nariaki , Monden Morito , Doki Yuichiro , Mori Masaki
Published: April 2023

LNs were collected within 3 hours after resection of the specimens with a disposable LN sampling kit that was prepared in a RNase-free state. In addition to routine pathological examination of LNs, representative five pericolic nodes adjacent to the tumor were cut into halves and stored in RNA laterTM at -20{degree sign}C. Immediately after pathological tests reported node-negative stage II CRC, RNA was extracted from LNs, checked for RNA quality, and then subjected to conventional RT-PCR for the CEA band and qRT-PCR for CEA mRNA value by the Light CyclerTM. Among seven CRC cases tested, Case No. 3, 4, and 6 were judged positive (Lower panel). Positivity of the CEA band was judged consistently by reference of the simultaneously produced control panel. One microgram of RNA from gastric cancer MKN45 cells and colon cancer LoVo cells was subjected to the RT reaction. Each cDNA was serially diluted at 1x10-1 to 1x10-5. PCR was performed using CEA primers and PBGD primers. A positive CEA band was visible at a 1x10-4 dilution in the MKN45 cells and at a 1x10-3 dilution in the LoVo cells (Upper panel).
Supplementary Figures 1 - 3 from Targeting Cancer Cells via the Reactive Oxygen Species-Mediated Unfolded Protein Response with a Novel Synthetic Polyphenol Conjugate
Authors: Shin Soon Young , Lee Jong Min , Lee Mi So , Koh Dongsoo , Jung Hyeryoung , Lim Yoongho , Lee Young Han
Published: April 2023

PDF file - 828K, Figure S1, Clonogenic assay Figure S2, QSAR Figure S3, Effect of polyphenol conjugates on the inhibition of clonogenicity Figure S4,(A) Effects of DPP-23 on the induction of apoptosis in HCT116 cells; (B) Effect of DPP-23 on the formation of LC3-II in various cells; (C)Effect of Beclin-1 silencing on the DPP-23-induced inhibition of clonogenicity; (D) Effect of pan-caspase inhibitors on DPP-23-induced LC3-II formation.
Supplementary Table 1 from DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy
Authors: Yeh Paul , Chen Heidi , Andrews Jenny , Naser Riyad , Pao William , Horn Leora
Published: April 2023

PDF file - 209K, EGFR Mutations Associated with Disease Control (Partial Response, Complete Response, or Stable Disease
Supplementary Figure 2 from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

Trop-2-dependent Akt signaling.
Supplementary Tables S1-3 from Elevated Serum Angiopoietin-like Protein 2 Correlates with the Metastatic Properties of Colorectal Cancer: A Serum Biomarker for Early Diagnosis and Recurrence
Authors: Toiyama Yuji , Tanaka Koji , Kitajima Takahito , Shimura Tadanobu , Kawamura Mikio , Kawamoto Aya , Okugawa Yoshinaga , Saigusa Susumu , Hiro Junichiro , Inoue Yasuhiro , Mohri Yasuhiko , Goel Ajay , Kusunoki Masato
Published: April 2023

Supplementary Tables S1-3. Table S1:Patient characteristics in the validation set, Table S2:Primer Sequences for KRAS and BRAF mutation analysis, Table S3:Comparison between ROC from screening step and validation step.
Supplementary Figure 5 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 58K, EphA2 protein is upregulated in clinical ccRCC tissues.
Data Supplement from p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Authors: Hardwick Nicola R. , Carroll Mary , Kaltcheva Teodora , Qian Dajun , Lim Dean , Leong Lucille , Chu Peiguo , Kim Joseph , Chao Joseph , Fakih Marwan , Yen Yun , Espenschied Jonathan , Ellenhorn Joshua D. I. , Diamond Don J. , Chung Vincent
Published: April 2023

Caption for Supplementary Table 1, Legends for Supplementary Figures 1 and 2
Supplemental Figure legends from Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
Authors: Yoshida Tatsuya , Ishii Genichiro , Goto Koichi , Neri Shinya , Hashimoto Hiroko , Yoh Kiyotaka , Niho Seiji , Umemura Shigeki , Matsumoto Shingo , Ohmatsu Hironobu , Iida Shinsuke , Niimi Akio , Nagai Kanji , Ohe Yuichiro , Ochiai Atsushi
Published: April 2023

Supplemental Figure legends
Supplementary Table 1, Figures 1 - 3 from Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection
Authors: O'Brien Darragh P. , Sandanayake Neomal S. , Jenkinson Claire , Gentry-Maharaj Aleksandra , Apostolidou Sophia , Fourkala Evangelia-Ourania , Camuzeaux Stephane , Blyuss Oleg , Gunu Richard , Dawnay Anne , Zaikin Alexey , Smith Ross C. , Jacobs Ian J. , Menon Usha , Costello Eithne , Pereira Stephen P. , Timms John F.
Published: April 2023

PDF file - 206K, Table S1 Numbers of test positive cases and controls using CA19-9 37 U/mL and CA125 30 U/mL cut-offs Figure S1 Scatter plots showing distribution of CA19-9, CA125, CEACAM1 and REG3A levels against time to diagnosis for discovery set. Zero represents the point of clinical diagnosis. Figure S2 Examples of CA19-9 and CA125 levels in individual cases with serial/longitudinal samples. Figure S3 Box and whisker plots showing serum levels of CA19-9 and CA125 for case control validation samples grouped into different time to diagnosis groups. Whisker limits represent the 5th and 95th percentiles, the box limits represent interquartile range, the horizontal line the median and the cross the mean. Case and control groups were compared using the Mann-Whitney test; significant P values (<0.05) are shown above the plots.
Supplementary Tables 1 - 3 from Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Authors: Lin Jie , Sampath Deepak , Nannini Michelle A. , Lee Brian B. , Degtyarev Michael , Oeh Jason , Savage Heidi , Guan Zhengyu , Hong Rebecca , Kassees Robert , Lee Leslie B. , Risom Tyler , Gross Stefan , Liederer Bianca M. , Koeppen Hartmut , Skelton Nicholas J. , Wallin Jeffrey J. , Belvin Marcia , Punnoose Elizabeth , Friedman Lori S. , Lin Kui
Published: April 2023

XLSX file - 74K, Table S1. Enzymatic potency, selectivity and cellular potency of GDC-0068 Table S2. GDC-0068 IC50 profile on cell viability and genetic background of cancer cell lines Table S3. Maximum percent body weight changes of mice treated with GDC-0068 single agent and in combination with chemotherapeutic agents
Data Supplement from Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
Authors: Naipal Kishan A.T. , Verkaik Nicole S. , Ameziane Najim , van Deurzen Carolien H.M. , ter Brugge Petra , Meijers Matty , Sieuwerts Anieta M. , Martens John W. , O'Connor Mark J. , Vrieling Harry , Hoeijmakers Jan H.J. , Jonkers Jos , Kanaar Roland , de Winter Johan P. , Vreeswijk Maaike P. , Jager Agnes , van Gent Dik C.
Published: April 2023

Figure S1: Schematic workflow of RAD51IRIF assay and accessory experimental timeline. Figure S2: Validation of RAD51 IRIF immunostaining: 2 hours post IR is optimal for RAD51 focus formation which are only formed in GEMININ positive cells Figure S3: áµž-H2AX and 53BP1 nuclear foci indicate the induction of DSBs in tissue slices Figure S4: Non-tumor cells display normal formation of RAD51 foci in tumor samples with impaired RAD51 IRIF formation Figure S5: Mutation and methylation analysis of impaired RAD51 IRIF tumors Figure S6: Tumor samples with BRCA1 promoter methylation displayed no in situ detection of BRCA1 mRNA Table S1: Complete overview of all tumor samples including Clinico-pathological characteristics Table S2: Clinico-pathological characteristics of Geminin positive vs Geminin negative tumor samples
Supplementary Figures 1 - 7 from Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Authors: Brown Jason R. , Wimberly Hallie , Lannin Donald R. , Nixon Christian , Rimm David L. , Bossuyt Veerle
Published: April 2023

Supplemental Figure 1. Schematic for multiplexed immunofluorescence staining for tumor infiltrating lymphocytes. Supplemental Figure 2. Comparison between AQUA scores within the total compartment and AQUA scores calculated within the stromal compartment and tumor mask. Supplemental Figure 3. Reproducibility of quantitative immunofluoresence assay on serial sections of an invasive breast tissue microarray. AQUA scores for (A) stromal CD3 expression, (B) stromal CD8 expression, (C) stromal CD20 expression have excellent correlation on two serial sections of index microarrays stained independently alongside the neoadjuvant cohort. Supplemental Figure 4. Correlation between TIL AQUA scores and clinicopathologic characteristics. Supplemental Figure 5. Determination of cutpoints between low and high expression of TIL biomarkers. Supplemental Figure 6. Sensitivity and specificity for AQUA analysis of CD3, CD8, and CD20 and histopathologic assessment of TILs on H&E slides.
Supplementary Figure 2 from Complete Regression of Metastatic Renal Cell Carcinoma by Multiple Injections of Engineered Mesenchymal Stem Cells Expressing Dodecameric TRAIL and HSV-TK
Authors: Kim Sae Won , Kim Su Jin , Park Sang Hoon , Yang Hyun Gul , Kang Moon Cheol , Choi Young Woo , Kim Seong Muk , Jeun Sin-Soo , Sung Young Chul
Published: April 2023

PDF file - 58K, Dose-dependent induction of apoptosis by dodecameric TRAIL expressing MSCs
Supplementary Materials and Methods from Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Authors: Suryawanshi Swati , Huang Xin , Elishaev Esther , Budiu Raluca A. , Zhang Lixin , Kim SungHwan , Donnellan Nicole , Mantia-Smaldone Gina , Ma Tianzhou , Tseng George , Lee Ted , Mansuria Suketu , Edwards Robert P. , Vlad Anda M.
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S2 from Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
Authors: Nickerson Michael L. , Dancik Garrett M. , Im Kate M. , Edwards Michael G. , Turan Sevilay , Brown Joseph , Ruiz-Rodriguez Christina , Owens Charles , Costello James C. , Guo Guangwu , Tsang Shirley X. , Li Yingrui , Zhou Quan , Cai Zhiming , Moore Lee E. , Lucia M. Scott , Dean Michael , Theodorescu Dan
Published: April 2023

Bladder cancer network containing debiquitinating enzymes (DUBs), chromosome remodeling genes and genes associated with VEGF signaling.
Suppl Table S3 from Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Authors: Suryawanshi Swati , Huang Xin , Elishaev Esther , Budiu Raluca A. , Zhang Lixin , Kim SungHwan , Donnellan Nicole , Mantia-Smaldone Gina , Ma Tianzhou , Tseng George , Lee Ted , Mansuria Suketu , Edwards Robert P. , Vlad Anda M.
Published: April 2023

Suppl Table S3. Top five networks from different group comparisons, identified via Ingenuity Pathway Analyses
Suppl Table S2 from Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Authors: Suryawanshi Swati , Huang Xin , Elishaev Esther , Budiu Raluca A. , Zhang Lixin , Kim SungHwan , Donnellan Nicole , Mantia-Smaldone Gina , Ma Tianzhou , Tseng George , Lee Ted , Mansuria Suketu , Edwards Robert P. , Vlad Anda M.
Published: April 2023

Suppl Table S2. Top five canonical pathways from different group comparisons, identified via Ingenuity Pathway Analyses
Suppl Fig S3 from Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer
Authors: Suryawanshi Swati , Huang Xin , Elishaev Esther , Budiu Raluca A. , Zhang Lixin , Kim SungHwan , Donnellan Nicole , Mantia-Smaldone Gina , Ma Tianzhou , Tseng George , Lee Ted , Mansuria Suketu , Edwards Robert P. , Vlad Anda M.
Published: April 2023

Suppl Fig S3. Antibody-mediated, complement-induced cytotoxicity
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Supplementary Table S2. Comparison of mutation events across different subgroups. (A) Summary of mutation events across different subgroups. Mutation event difference between: (B) Smokers vs non-smokers, (C) Drinkers vs non-drinkers, (D) Large primary vs small primary, (E) Node positive vs node negative, (F) Failure vs non-failure.
Data Supplement from Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
Authors: Seiwert Tanguy Y. , Zuo Zhixiang , Keck Michaela K. , Khattri Arun , Pedamallu Chandra S. , Stricker Thomas , Brown Christopher , Pugh Trevor J. , Stojanov Petar , Cho Juok , Lawrence Michael S. , Getz Gad , Brägelmann Johannes , DeBoer Rebecca , Weichselbaum Ralph R. , Langerman Alexander , Portugal Louis , Blair Elizabeth , Stenson Kerstin , Lingen Mark W. , Cohen Ezra E.W. , Vokes Everett E. , White Kevin P. , Hammerman Peter S.
Published: April 2023

Supplementary Data 1. Somatic mutations in 120 HNC patients in MAF format. List of somatic mutations with the mutated gene name, genomic location, dbSNP id and predicted change in protein.
Supplementary Figure Legend from Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Authors: Chan Christine M. , Jing Xia , Pike Laura A. , Zhou Qiong , Lim Dong-Jun , Sams Sharon B. , Lund Gregory S. , Sharma Vibha , Haugen Bryan R. , Schweppe Rebecca E.
Published: April 2023

PDF file, 49KB.
Supplementary Figure 1 from Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Authors: Chan Christine M. , Jing Xia , Pike Laura A. , Zhou Qiong , Lim Dong-Jun , Sams Sharon B. , Lund Gregory S. , Sharma Vibha , Haugen Bryan R. , Schweppe Rebecca E.
Published: April 2023

PDF file, 242KB, Histologic analysis of BCPAP metastatic tumors.
Supplementary Figure 3 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Authors: Psyrri Amanda , Lee Ju-Whei , Pectasides Eirini , Vassilakopoulou Maria , Kosmidis Efstratios K. , Burtness Barbara A. , Rimm David L. , Wanebo Harold J. , Forastiere Arlene A.
Published: April 2023

PDF file - 53K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by PIK3CA, PTEN, and Akt cluster status.
Supplementary Table 3 from Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
Authors: Gavin Patrick G. , Colangelo Linda H. , Fumagalli Debora , Tanaka Noriko , Remillard Matthew Y. , Yothers Greg , Kim Chungyeul , Taniyama Yusuke , Kim Seung Il , Choi Hyun Joo , Blackmon Nicole L. , Lipchik Corey , Petrelli Nicholas J. , O'Connell Michael J. , Wolmark Norman , Paik Soonmyung , Pogue-Geile Kay L.
Published: April 2023

XLS file - 154K, Freqeuncy of Mutations in NSABP C-07 and C-08 and in COSMIC
Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Authors: Gupta Shiv K. , Mladek Ann C. , Carlson Brett L. , Boakye-Agyeman Felix , Bakken Katrina K. , Kizilbash Sani H. , Schroeder Mark A. , Reid Joel , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S3. Evidence of pluripotency in cells of PDX line GBM12 and derivative sublines
Supplementary Figure S2 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Authors: Lee Yunqin , Shin June Ho , Longmire Michelle , Wang Hua , Kohrt Holbrook E. , Chang Howard Y. , Sunwoo John B.
Published: April 2023

Supplementary Figure S2. Characterization of CD44- and CD44+ SCCHN cells.
Supplementary Table 1 from Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma
Authors: Radon Tomasz P. , Massat Nathalie J. , Jones Richard , Alrawashdeh Wasfi , Dumartin Laurent , Ennis Darren , Duffy Stephen W. , Kocher Hemant M. , Pereira Stephen P. , Guarner (posthumous) Luisa , Murta-Nascimento Cristiane , Real Francisco X. , Malats Núria , Neoptolemos John , Costello Eithne , Greenhalf William , Lemoine Nick R. , Crnogorac-Jurcevic Tatjana
Published: April 2023

Expression of non-redundant proteins identified by GeLC-MS/MS from males and females in healthy controls, chronic pancreatitis and pancreatic adenocarcinoma patients.